Roundtable: Aligning Platform Selection to Clinical, Biological & Commercial Objectives
- Debate real-world trade-offs across timeline, tissue targeting, safety, manufacturability, and IP boundaries to inform strategy
- Evaluate modality-to-indication fit through case scenarios to improve development efficiency and reduce failure risk
- Align stakeholder priorities (clinical, regulatory, BD, IP) to ensure long-term portfolio viability and investment readiness